Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BNIP3P31 is a human pseudogene in the BNIP3 gene family, formally named "BCL2 interacting protein 3 pseudogene 31" and abbreviated as BNIP3P31. It does not encode a functional protein and is classified as a pseudogene in genomic databases. Although pseudogenes are not targets for direct therapeutic intervention, some—like BNIP3P31—may have regulatory roles via RNA-mediated mechanisms. Specifically, a related pseudogene, BNIP3P1, has been shown to act as a competing endogenous RNA regulating the expression of BNIP3 and modulating cell proliferation and apoptosis in preeclampsia, but there is no evidence that BNIP3P31 itself has confirmed functional or disease roles. BNIP3P31 is not a canonical therapeutic target such as a receptor, enzyme, or transporter, and no drugs or mechanisms of action are associated with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 31 (BNIP3P31).